MedTrace Logo

Eosinophil and Anticoagulation in COVID-19 Patients

NCT04507282 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2020-08-18

No results posted yet for this study

Summary

Despite prophylactic anticoagulant treatments, thrombotic complications may develop in patients with Coronavirus disease 2019 (COVID-19). This study aimed to evaluate anti-Factor Xa levels to determine the anticoagulant activity of low molecular weight heparin (LMWH) in COVID-19 patients.

Conditions

Interventions

DRUG

LMWH

COVID 19 positive patients anticogulation level, subprophylactic level and prophylactic level

Sponsors & Collaborators

  • Bursa Postgraduate Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-15
Primary Completion
2020-07-01
Completion
2020-07-15
FDA Drug
Yes

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04507282 on ClinicalTrials.gov